Protonation equilibrium and lipophilicity of moxifloxacinLANGLOIS, Marie-Hélène; MONTAGUT, Martine; DUBOST, Jean-Pierre et al.Journal of pharmaceutical and biomedical analysis. 2005, Vol 37, Num 2, pp 389-393, issn 0731-7085, 5 p.Article

Gender Analysis of Moxifloxacin Clinical TrialsCHILET-ROSELL, Elisa; RUIZ-CANTERO, Ma Teresa; PARDO, Ma Angeles et al.Journal of women's health (Larchmont, N.Y. 2002). 2014, Vol 23, Num 1, pp 77-104, issn 1540-9996, 28 p.Article

Biological assay and liquid chromatographic method for analysis of moxifloxacin in tabletsGUERRA, Fanny L. B; PAIM, Clesio S; STEPPE, Martin et al.Journal of AOAC International. 2005, Vol 88, Num 4, pp 1086-1092, issn 1060-3271, 7 p.Article

Structural identification and characterization of impurities in moxifloxacinRAVINDRA KUMAR, Y; PRASAD RAJU, V. V. N. K. V; RAJESH KUMAR, R et al.Journal of pharmaceutical and biomedical analysis. 2004, Vol 34, Num 5, pp 1125-1129, issn 0731-7085, 5 p.Article

Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002)BETRIU, Carmen; RODRIGUEZ-AVIAL, Iciar; GOMEZ, Maria et al.Diagnostic microbiology and infectious disease. 2005, Vol 53, Num 3, pp 221-223, issn 0732-8893, 3 p.Article

Enantiomeric purity assay of moxifloxacin hydrochloride by capillary electrophoresisCRUZ, Lou Ann; HALL, Rex.Journal of pharmaceutical and biomedical analysis. 2005, Vol 38, Num 1, pp 8-13, issn 0731-7085, 6 p.Article

Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo SimulationLANDERSDORFER, Cornelia B; KINZIG, Martina; HENNIG, Friedrich F et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 5, pp 2074-2081, issn 0066-4804, 8 p.Article

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT StudiesBLOOMFIELD, D. M; KOST, J. T; GHOSH, K et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 4, pp 475-480, issn 0009-9236, 6 p.Article

New drugs for the treatment of tuberculosis: hope and realityGROSSET, J. H; SINGER, T. G; BISHAI, W. R et al.The International journal of tuberculosis and lung disease. 2012, Vol 16, Num 8, pp 1005-1014, issn 1027-3719, 10 p.Article

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experiencePRANGER, A. D; VAN ALTENA, R; AARNOUTSE, R. E et al.The European respiratory journal. 2011, Vol 38, Num 4, pp 888-894, issn 0903-1936, 7 p.Article

Bactericidal Activity of Moxifloxacin on Exponential and Stationary Phase Cultures of Mycobacterium tuberculosisSULOCHANA, S; MITCHISON, D. A; KUBENDIREN, G et al.Journal of chemotherapy (Testo stampato). 2009, Vol 21, Num 2, pp 127-134, issn 1120-009X, 8 p.Article

Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacinPIERSIMONI, Claudio; LACCHINI, Carla; PENATI, Valeria et al.Diagnostic microbiology and infectious disease. 2007, Vol 57, Num 3, pp 283-287, issn 0732-8893, 5 p.Article

Anti-inflammatory effects of moxifloxacin and human β-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharideDONNARUMMA, Giouanna; PAOLETTI, Iole; BUOMMINO, Elisabetta et al.Peptides (New York, NY. 1980). 2007, Vol 28, Num 12, pp 2286-2292, issn 0196-9781, 7 p.Article

Comparative elution of moxifloxacin from Norian skeletal repair system and acrylic bone cement : an in vitro studyKANELLAKOPOULOU, Kyriaki; TSAGANOS, Thomas; ATHANASSIOU, Kalomira et al.International journal of antimicrobial agents. 2006, Vol 28, Num 3, pp 217-220, issn 0924-8579, 4 p.Article

Acute interstitial nephritis associated with moxifloxacin useARGIROV, Michael; RICKEN, Gesa; ZECHER, Daniel et al.Clinical therapeutics. 2005, Vol 27, Num 8, pp 1260-1263, issn 0149-2918, 4 p.Article

Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy malesSTASS, H; KUBITZA, D; MÖLLER, J.-G et al.British journal of clinical pharmacology. 2005, Vol 59, Num 5, pp 536-541, issn 0306-5251, 6 p.Article

Efficacy of the latest fluoroquinolones against experimental Yersinia pestisSTEWARD, J; LEVER, M. S; RUSSELL, P et al.International journal of antimicrobial agents. 2004, Vol 24, Num 6, pp 609-612, issn 0924-8579, 4 p.Article

Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: Advantage of IE over other integral parametersFIRSOV, A. A; ZINNER, S. H; LUBENKO, I. Y et al.Chemotherapy (Basel). 2002, Vol 48, Num 6, pp 275-279, issn 0009-3157, 5 p.Article

Moxifloxacin in Complicated Skin and Skin Structure Infections (cSSSIs): A Prospective, International, Non-Interventional, Observational StudyBOGNER, Johannes R; KUTAIMAN, Ammar; ESGUERRA-ALCALEN, Melanie et al.Advances in therapy. 2013, Vol 30, Num 6, pp 630-643, issn 0741-238X, 14 p.Article

Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatmentLAMUNU, D; CHAPMAN, K. N; MASTRANUNZIO, S et al.The International journal of tuberculosis and lung disease. 2012, Vol 16, Num 4, pp 480-485, issn 1027-3719, 6 p.Article

Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelinesAMBLER, Jane; RENNIE, Robert; POUPARD, James et al.Diagnostic microbiology and infectious disease. 2008, Vol 61, Num 1, pp 49-57, issn 0732-8893, 9 p.Article

Plasma protein binding of fluoroquinolones affects antimicrobial activityZEITLINGER, Markus; SAUERMANN, Robert; FILLE, Manfred et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 61, Num 3, pp 561-567, issn 0305-7453, 7 p.Article

In vitro development of resistance to DX-619 and other quinolones in enterococciWICKMAN, Paul A; BLACK, Jennifer A; MOLAND, Ellen Smith et al.Journal of antimicrobial chemotherapy (Print). 2006, Vol 58, Num 6, pp 1268-1273, issn 0305-7453, 6 p.Article

Pseudo-uvéite sévère associée à l'utilisation de moxifloxacine = Severe pseudouveitis associated with moxifloxacin therapyDUNCOMBE, A; GUEUDRY, J; MASSY, N et al.Journal français d'ophtalmologie. 2013, Vol 36, Num 2, pp 146-150, issn 0181-5512, 5 p.Article

Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With TuberculosisPRANGER, Arianna D; KOSTERINK, Jos G. W; VAN ALTENA, Richard et al.Therapeutic drug monitoring. 2011, Vol 33, Num 3, pp 350-354, issn 0163-4356, 5 p.Article